Evidence map›Paper›PMID 34062737›Full record

ArticleMolecules (Basel, Switzerland)2021

Olive-Derived Triterpenes Suppress SARS COV-2 Main Protease: A Promising Scaffold for Future Therapeutics.

Hani A Alhadrami, Ahmed M Sayed, Ahmed M Sharif, Esam I Azhar, Mostafa E Rateb

Open access · goldAbstract read
In one paragraph

Article in Molecules (Basel, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.

0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed
3.7field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

28 citing papers in PubMed, 51 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Article
  6. Review
  7. Review
  8. Article
  9. Review
  10. Article
  11. Cheminformatics-Based Study Identifies Potential Ebola VP40 Inhibitors.International journal of molecular sciences · 2023
    Article
  12. Article
  13. Article
  14. Article
  15. A Comprehensive In Silico Study of New Metabolites fromMolecules (Basel, Switzerland) · 2022
    Article
  16. Article
  17. Recent Advances in Antiviral Activities of Triterpenoids.Pharmaceuticals (Basel, Switzerland) · 2022
    Review
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 3 countries.

Hani A AlhadramiDepartment of Medical Laboratory Technology, Faculty of Applied Medical Sciences, King Abdulaziz University, P.O. Box 80402, Jeddah 21589, Saudi Arabia.ORCID 0000-0002-4822-1895
Ahmed M SayedDepartment of Pharmacognosy, Faculty of Pharmacy, Nahda University, Beni-Suef 62513, Egypt.ORCID 0000-0002-1442-183X
Ahmed M SharifSpecial Infectious Agent Unit, King Fahd Medical Research Centre, King Abdulaziz University, P.O. Box 80402, Jeddah 21589, Saudi Arabia.
Esam I AzharDepartment of Medical Laboratory Technology, Faculty of Applied Medical Sciences, King Abdulaziz University, P.O. Box 80402, Jeddah 21589, Saudi Arabia.ORCID 0000-0002-1736-181X
Mostafa E RatebSchool of Computing, Engineering & Physical Sciences, University of the West of Scotland, Paisley PA1 2BE, UK.ORCID 0000-0003-4043-2687
King Abdulaziz University · SANahda University · EGUniversity of the West of Scotland · GB

Funding

the Saudi Ministry of Health contract number 16581700012 - project number 581
6 · The paper itself

Abstract

SARS CoV-2 pandemic is still considered a global health disaster, and newly emerged variants keep growing. A number of promising vaccines have been recently developed as a protective measure; however, cost-effective treatments are also of great importance to support this critical situation. Previously, betulinic acid has shown promising antiviral activity against SARS CoV via targeting its main protease. Herein, we investigated the inhibitory potential of this compound together with three other triterpene congeners (i.e., ursolic acid, maslinic acid, and betulin) derived from olive leaves against the viral main protease (M

Indexed as

COVID-19 Drug TreatmentAntiviral AgentsBetulinic AcidCoronavirus 3C ProteasesCOVID-19HumansMolecular Docking SimulationMolecular Dynamics SimulationOleaOleanolic AcidPentacyclic TriterpenesProtease InhibitorsSARS-CoV-2TriterpenesUrsolic Acid3C-like proteinase, SARS-CoV-2Antiviral AgentsbetulinBetulinic AcidCoronavirus 3C Proteasesmaslinic acidOleanolic AcidPentacyclic TriterpenesProtease InhibitorsTriterpenesUrsolic AcidCOVID-19in-silicomain proteasemolecular dynamic simulationolive leavesSARS CoV-2triterpenes

Identifiers

PMID34062737
PMCPMC8125615
OpenAlexW3157722042

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.